跳至主要内容
临床试验/NCT00253266
NCT00253266已完成4 期

Comparison of Venlafaxine Augmentation With Quetiapine v.s. Placebo in Treatment Resistant Depression

Max-Planck-Institute of Psychiatry1 个研究点 分布在 1 个国家目标入组 126 人开始时间: 2008年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
126
试验地点
1
主要终点
Hamilton Depression Rating Scale (HDRS)

研究概览

简要总结

This is an assessment of the efficacy of venlafaxine-HCL augmentation with the neuroleptic quetiapine in treatment resistant depression.

详细描述

We examine the efficacy of Venlafaxine-HCL augmentation with the neuroleptic Quetiapine in treatment resistant depression in a double-blind randomized clinical trial. Secondary objective is the evaluation of pharmacogenetic factors contributing to drug efficacy in treatment resistant depression.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
20 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Female and male inpatients with a major depressive disorder without psychotic features or with a depressive episode within a bipolar I or II disorder without psychotic features
  • Ages between 20 and 70 years
  • Total score greater than 18 on the Hamilton Depression Rating Scale
  • Documentation of at least one ineffective antidepressant drug trial under adequate dosage for at least 6 weeks in the current episode

排除标准

  • Other psychiatric axis I disorders than those mentioned as Inclusion criteria
  • Acute suicidality (Item 3 of the Hamilton Depression Rating Scale greater than 2)
  • Drug or alcohol addiction
  • Patients with severe hepatic, cardiovascular, neurologic, metabolic or malignant disorders
  • Documentation or report of a previous ineffective treatment trial with venlafaxine, lamotrigine or quetiapine
  • Functional kidney disorders
  • Untreated hypertension
  • Acute treatment with thyroid hormone (less than 3 months)
  • Pregnant or nursing patients
  • Women of childbearing age without effective contraception

研究组 & 干预措施

Verum

Experimental

Quetiapine augmentation

干预措施: Venlafaxine (Drug)

Verum

Experimental

Quetiapine augmentation

干预措施: Quetiapine (Drug)

Placebo

Placebo Comparator

"Placebo" augmentation

干预措施: Venlafaxine (Drug)

结局指标

主要结局

Hamilton Depression Rating Scale (HDRS)

时间窗: after monotherapy and after augmentation

次要结局

  • Cognitive function(after monotherapy and after augmentation)
  • Self reported psychopathology (Beck Depression Inventory [BDI], State-Trait Anxiety Inventory [STAI])(after monotherapy and after augmentation)

研究者

发起方
Max-Planck-Institute of Psychiatry
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验